tyrosine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Tyrosine (L-form) is a non-essential amino acid, which is primarily required for the protein synthesis. This amino acid is the precursor of dopamine, norepinephrine, and epinephrine; therefore the lower concentration of tyrosine could be a peripheral marker of the hyperdopaminergic condition hypothesized to explain psychosis. Tyrosine supplements can improve cognition, increase energy, reduce anxiety, reduce depression, reduce levels of pain.   NCATS

Chemistry

  • SMILES: N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
  • InChIKey: OUYCCCASQSFEME-QMMMGPOBSA-N
  • Mol. Mass: 181.1885
  • ALogP: 0.35
  • ChEMBL Molecule:
    tyrosine  
More Chemistry

Pharmacology

  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid | 4-hydroxy-l-phenylalanine | l-tyrosin | l-tyrosine | (s)-2-amino-3-(p-hydroxyphenyl)propionic acid | (s)-3-(p-hydroxyphenyl)alanine | (s)-alpha-amino-4-hydroxybenzenepropanoic acid | (s)-tyrosine | (s)-(-)-tyrosine | (s)-α-amino-4-hydroxybenzenepropanoic acid | tyr | tyrosine | y | (−)-α-amino-p-hydroxyhydrocinnamic acid

Organizations (16)

Research & Development (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (2)


 

Diabetes Mellitus, Type 2

Nutrition Disorders (approved 1975)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Blood Pressure (Early Phase 1)

Myopathies, Nemaline (Phase 2)

Obesity (Phase 2/Phase 3)

Sepsis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial Organizations: 16

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue